PHP195 Methods  Online research was completed by market access executives across a range of top 25 global pharma companies, as well as several smaller companies.  The research focused on four main topics:  how market access was defined by their company  what market access training is currently provided  the extent to which different teams receive market access training  the nature of their company's priority market access training needs  Feedback from 32 responses were analysed.
Discussion and conclusions
 Setting the price and obtaining market access for a new pharmaceutical remains one of the biggest commercial challenges facing manufacturers. As the payer landscape becomes increasingly challenging, demonstrating product value and considering the payer perspective as early as possible in clinical development is increasingly important.
 The objective of this research was to determine how the pharmaceutical industry is investing in their market access training capabilities in order to address the needs of today's complex market access landscape.
 It is clear from our survey that companies are not placing sufficient focus on their market access capabilities across the organisation.
 Market Access teams can be under-resourced, lacking expertise and headcount, particularly among affiliates. Furthermore, limited infrastructure is in place to encourage collaboration between Market Access and R&D teams.
 Market access training should be provided beyond Market Access teams, such as Medical Affairs and Clinical Development. By not training such teams, companies are missing an opportunity to implement a more integrated, cross-functional approach to evidence generation that proactively addresses payer needs early in the development process.
 Despite resourcing and expertise limitations, companies currently rely heavily on internal teams to deliver their market access training. External providers are used in only a limited manner.
 There are a number of key market access challenges facing pharmaceutical companies (Table 1)  Overall consensus was that there is a general lack of market access expertise (44%) and investment (41%) facing pharmaceutical companies and their products. This is despite 38% of respondents feeling the increasingly challenging and sophisticated payer environment is a key market access challenge.  "Achieving reimbursement" and "ensuring patient access" are the most common definitions of market access, although for some "market access" is simply limited to price negotiations or even just regulatory approval. (Figure 1 )  Few respondents currently benefit from comprehensive training programmes that cover a full range of key market access topics, with less than 50% trained in managed entry agreements, health economics, health technology assessments and real-world evidence. (Table 2 ) 
